New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
08:11 EDTAMPEAmpio announces positive results from Ampion study
Ampio Pharmaceuticals announced the one month results of the open label portion of the multiple injections of Ampion into the knees of patients with osteoarthritis, or OA. Company explained "This first part of the multiple injections study involved patients receiving a series of three 4ml injections of Ampion intra-articularly. In order to proceed with the randomized vehicle- controlled portion of the trial, we had to repeat a demonstration of both safety and efficacy even though efficacy and safety had been demonstrated previously in the single injection SPRING study. No serious drug related adverse events were reported in either trial. The WOMAC A pain score improved by 65% from baseline with the multiple injections at one month post injection compared to 33% in the SPRING study at the same time point. In addition, the function score WOMAC C compared to baseline improved by 74 % at 4 weeks. The study also includes serial high resolution MRI's at various time points that will explore whether there are clinical benefits beyond pain relief."
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 22, 2015
08:31 EDTAMPEAmpio announces additional study ersults for Optina
Ampio announced that further data analysis from the 12-week multi-center, placebo-controlled, double-masked randomized trial identified a reversal of pathological changes and a synergistic effect with other medication. As previously reported, oral treatment with Optina has been shown to be safe and confer significant improvements in visual acuity (VA) and reductions in central retinal thickness in patients with diabetic macular edema when given the optimal dose. An independent specialized ophthalmology company reviewed a representative set of images of the eye from the trial and identified positive changes in Optina treated patients compared to placebo. These changes included the reversal of complications such as cystic lesions and subretinal fluid. Additionally, analysis revealed that 69% of the patients in the Optina™ Study received a standard of care medication that manages kidney-induced high blood pressure. The drugs referred to as ACE Inhibitors or ARBs are commonly prescribed to diabetic patients. When this group received the optimal Optina™ dose, they showed a six-letter improvement compared to placebo, regardless of whether or not they previously had anti-VEGF eye injections. There was a significant 34 micron reduction in central retinal thickness over placebo. 60% of these eyes showed a restoration of at least one line of vision compared to only 27% of placebo.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use